Share this article

Aurinia Pharmaceuticals has initiated an open-label exploratory trial to analyse the antiviral effects of voclosporin in kidney transplant recipients (KTRs) with Covid-19.

Aurinia also secured funding for the VOCOVID study.

Voclosporin is a novel calcineurin inhibitor (CNI) used for treating patients with lupus nephritis. 

The drug hinders IL-2 expression and minimises T-cell mediated immune responses while synergistically stabilising podocytes in the kidney. 

Organ transplant recipients with Covid-19 infection are at high risk for complications as they need daily immunosuppressive medications to prevent organ rejection. 

In prior in-vitro studies, calcineurin inhibitors (CNIs) like voclosporin have demonstrated viral replication inhibition properties. 

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData

The single-centre and investigator-initiated trial (IIT) is being carried out by Dr Aiko de Vries and Dr YK Onno Teng at the Leiden University Medical Center (LUMC) in the Netherlands.

Aurinia Pharmaceuticals Research executive vice-president Robert Huizinga said: “Working with our long-time collaborators at LUMC, we established the preclinical antiviral activity of voclosporin against the SARS-CoV-2 virus with results that further highlight voclosporin’s differentiation from legacy CNIs.

“As we continue to prepare for potential FDA approval and commercial launch of voclosporin for the treatment of LN, we are pleased to test the potential of voclosporin to meet the urgent needs of this specific patient population driven by the Covid-19 pandemic.”

The 56-day trial will assess the antiviral effects of voclosporin compared to tacrolimus in stable KTRs who contracted SARS-CoV-2.

It will randomise 20 KTRs testing positive for Covid-19 who are on dual immunosuppressives of prednisone and tacrolimus at study entry to remain on tacrolimus or be switched to voclosporin.

The trial’s primary endpoint is the reduction in SARS-CoV-2 viral load over 56 days.

Furthermore, it will evaluate predefined endpoints as surrogate markers of improved viral clearance, including time to three-log reduction in viral load concentration and time to clinical recovery.